ArticleRisk management and healthcare policy2025
Analysis of the Clinical Symptom Improvement and Recurrence Rate in Chronic Suppurative Otitis Media Patients Treated with Combination Therapy: Combination of Ofloxacin and Dexamethasone.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of levofloxacin combined with dexamethasone ear drops on suppurative otitis media and analysis of influencing factors.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the clinical symptom improvement and recurrence rate of chronic suppurative otitis media (CSOM) patients treated with a combination therapy regimen (combination of ofloxacin and dexamethasone). Methods: Based on the treatment regimen, patients were divided into two groups: the control group was treated with dexamethasone, while the treatment group received a combination of ofloxacin and dexamethasone. The clinical symptom improvement, hearing evaluation, pathogen clearance rate, inflammatory marker detection, adverse reactions, recurrence rate and recurrence rate post-treatment were compared between the two groups. Results: There were no significant differences in the baseline clinical data between the two groups (P > 0.05). The overall clinical efficacy of the treatment group was significantly higher than that of the control group (P < 0.05). After treatment, the improvements in air conduction (AC) and air-bone gap (ABG) in the treatment group were significantly greater than those in the control group (P < 0.05). The time for the resolution of tympanic membrane congestion and the healing of perforations was shorter in the treatment group compared to the control group (P < 0.05). The pathogen clearance rate in the treatment group was significantly higher than in the control group (P < 0.05). After treatment, levels of inflammatory markers IL-8, TGF-β1, and PCT in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion: The combination therapy of ofloxacin and dexamethasone significantly improves the clinical symptoms, reduces the recurrence rate, and lowers the incidence of adverse reactions in chronic suppurative otitis media patients. It shows significant clinical efficacy with improved hearing outcomes, and is worthy of clinical promotion. However, this study still has certain limitations, such as the possibility of introducing selection bias. In the future, prospective clinical trials with multiple centers and large samples can be conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.